Your session is about to expire
← Back to Search
Enzyme
Study of Latiglutenase in T1D/CD Patients
Phase 2
Waitlist Available
Led By David Maahs, MD
Research Sponsored by Entero Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Summary
This trial studies people with both Type 1 diabetes and celiac disease who have been on a gluten-free diet for a significant period. The goal is to see if avoiding gluten helps manage both conditions better. By not eating gluten, these patients can prevent their immune system from damaging their intestines, which might also help control their diabetes.
Eligible Conditions
- Celiac Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Symptom Severity Reduction
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: LatiglutenaseActive Control1 Intervention
IMGX003
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Find a Location
Who is running the clinical trial?
Entero TherapeuticsLead Sponsor
9 Previous Clinical Trials
397 Total Patients Enrolled
2 Trials studying Celiac Disease
123 Patients Enrolled for Celiac Disease
Immunogenics, LLCIndustry Sponsor
3 Previous Clinical Trials
202 Total Patients Enrolled
3 Trials studying Celiac Disease
202 Patients Enrolled for Celiac Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,455 Previous Clinical Trials
4,335,095 Total Patients Enrolled
3 Trials studying Celiac Disease
441 Patients Enrolled for Celiac Disease
David Maahs, MDPrincipal InvestigatorStanford University